Illumina’s Donation to the Africa Centre for Disease Control and Prevention Expands their Capability for Sequencing-Based COVID-19 Surveillance
Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation of our sequencing systems and related consumables intended to expand SARS-CoV-2 sequencing capabilities and capacity in ten African countries, including the Democratic Republic of the Congo, Egypt, Ethiopia, Ghana, Kenya, Mali, Nigeria, Senegal, South Africa and Uganda.
Public Health institutions in Africa have been implementing Next-Generation Sequencing (NGS) based surveillance to drive a deeper understanding of endemic diseases and outbreaks. SARS-CoV-2 positive samples are currently being sequenced by only a few African institutions to characterize circulating strains. Africa CDC is now expanding the network of institutions with NGS capabilities to empower additional countries to rapidly characterize outbreak samples, without the need to ship samples across borders.
“It is critical to provide access to NGS technology throughout the world to drive a global response that will be effective in supporting SARS-CoV-2 control efforts, and ultimately, help improve human health,” said Illumina’s Senior Vice President and Chief Medical Officer, Dr. Phil Febbo. “This donation enables the Africa CDC to deeply understand the circulating virus throughout the continent, providing equitable access to important technology that can be used to help protect the health of the African population. With this outbreak, it has become clear that enabling local or regional proactive surveillance will benefit those immediately at risk as well as all of us around the globe.”
“Utilisation of NGS with COVID-19 pandemic by African institutions will facilitate the rapid and accurate identification of transmission pathways within and between populations and provide information on the probable source,” said Dr. Ahmed Ogwell Ouma, the Deputy Director of Africa CDC. “Such tools will ensure that African countries have robust and precise methods for identifying, comparing, and classifying pathogenic organisms in a timely manner. This donation will support Africa CDC’s program to strengthen NGS capacity within public health institutions on the African continent to better respond to current and future disease threats.”
Christian Happi, Professor of Molecular Biology and Genomics in the Department of Biological Sciences, and the Director of the African Center of Excellence for Genomics of Infectious Diseases (ACEGID), at Redeemer University in Nigeria, said: “Genomics represents the future of infectious disease control and treatment. The new reagents and equipment from Illumina are very timely. The ACEGID, together with other African institutions, has been mandated by the Africa CDC to contribute to the effort of sequencing coronavirus genomes across the continent to track the spread of the virus and its mutations. In order to do this, we need a lot of resources so we can not only support public health, but also contribute to international science and knowledge around this novel pathogen.”
“NGS enables countries to understand how the virus is introduced and spread, as well as perform contact tracing, design control measures, and monitor how the virus is evolving in ways that may affect pathogenicity, or the performance of diagnostics or therapies,” said Dr. Yenew Kebede head of the Division of Laboratory Systems and Networks at Africa CDC. By comparing the genomes of viral strains from different SARS-CoV-2 samples, public health officials can understand how the virus is moving through the population. This information can, in turn, direct mitigation and control measures, and eventually support efforts to reopen borders for transport and travel, once the outbreak subsides.
Paula Dowdy, General Manager, SVP, Illumina EMEA, said: “At Illumina, we believe that the 1.3 billion people in Africa deserve access to the best quality of life that can be delivered through genomics. We are very pleased to be able to support this network of laboratories with donations of essential equipment and reagents for the important work of the Africa CDC against coronavirus. Moreover, we value our strong relationships with these institutes not just at the time of this pandemic, but also more broadly as Africa continues to face other infectious disease epidemics.”
For Research Use Only. Not for use in diagnostic procedures.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements involve risks and uncertainties, including our expectations and beliefs regarding future conduct and growth of our business and the markets in which we operate. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) the impact of the COVID-19 pandemic to our business; (ii) challenges inherent in developing, and launching new products and services; (iii) the utility of such products and services; and (iv) the speed and scale of their adoption by customers, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.
Jacquie Ross, CFA
Dr Karen Birmingham, EMEA
+44 7500 105665
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newmont Publishes 2019 Sustainability Report1.6.2020 15:00:00 CEST | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT) (Newmont or The Company) today announced the publication of its 2019 Sustainability Report, Beyond the Mine, a transparent and comprehensive disclosure of the Company’s environmental, social and governance (ESG) performance. “Our sustainability report provides investors and other stakeholders a transparent and detailed look at look at our safety, environmental and social performance,” said Tom Palmer, President and Chief Executive Officer. “In 2019, we completed two transformative transactions whilst enhancing our ESG performance to align with our position as the world’s leading gold company.” Newmont’s 2019 sustainability highlights include: Achieving no workplace fatalities and conducting a global safety culture review, which identified several opportunities to enhance Newmont’s Fatality Risk Management program and improve the way fatality risks are managed Further strengthening management of tailings, whilst enhancing transparency through a
New Western Union research provides insight into the future of international education1.6.2020 15:00:00 CEST | Press release
The Western Union Company (NYSE: WU), a leader in cross-border, cross-currency money movement and payments, today shares a new report on “The Future of International Education,” in partnership with The Future Laboratory. The white paper highlights five new student profiles that will evolve from the shifting attitudes and behaviors of today’s youth. From Hybrid Thinkers to Greener Graduates, this new report predicts how academic institutions should adapt to meet these expectations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005162/en/ Meet the students of the future: new student profiles uncovered in “The Future of International Education” (Graphic: Business Wire) The findings come as universities and colleges worldwide are evolving to navigate COVID-19, from moving online, to delaying term dates. Institutions can use the report to ensure the new policies they introduce align with the needs and priorities of interna
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation1.6.2020 13:00:00 CEST | Press release
Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3 (PFIC3). PFIC3 is a rare life-threatening and chronically debilitating condition due to progressive severe liver dysfunction, accompanied by jaundice, portal hypertension, hepatosplenomegaly and failure to thrive. The symptoms of the disease usually appear first in childhood with progressive cholestasis, evolving to hepatic failure, cirrhosis and need for liver transplantation. “We are very pleased to receive these designations which further validate Vivet’s efforts to treat rare inherited metabolic disorders. The FDA and EC have both recognized the unmet need for a safe and effective treatment of PFIC3 and the potential of VTX-803 to address such need. The field of Progressive Familial Intrahepatic Cholest
FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure1.6.2020 13:00:00 CEST | Press release
The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005257/en/ Impella RP is now FDA indicated for COVID-19 related complications, including pulmonary embolism. (Photo: Business Wire) Impella RP is a temporary heart pump that provides circulatory support for patients who develop right side ventricular failure. Five years of pre- and post-market clinical studies support Impella RP’s safety and efficacy. In 2017, Impella RP received FDA approval as safe and effective for treating right ventricular failure in the setting of acute myocardial infarction and after cardiac surgery. Biventricular cardiac support can be provided when Impella RP is
Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast1.6.2020 13:00:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire Peak, one of the most globally successful mobile gaming companies, for $1.8 billion. Peak brings a 100-person strong team and two Forever Franchises, Toon Blast and Toy Blast, that have consistently ranked in the top 10 and top 20 U.S. iPhone grossing games for over two years, respectively. These franchises add significant scale to Zynga’s live services and will be an additional driver of margin expansion over the coming years. Peak also enhances Zynga’s new game pipeline with additional projects in early development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005142/en/ Zynga Enters Into Agreement to Acquire Istanbul-based Peak, Creator of Top Charting Mobile Franchises Toon Blast and Toy Blast (Graphic: Business Wire) Founded in 2010 by Sidar Sahin, Peak has developed the
bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 06:00:00 CEST | Press release
Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom